Prothena Corporation plc (NASDAQ:PRTA – Get Free Report) major shareholder William Scully purchased 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 17th. The stock was bought at an average price of $8.09 per share, with a total value of $404,500.00. Following the completion of the purchase, the insider owned 1,027,000 shares of the company’s stock, valued at $8,308,430. This trade represents a 5.12% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Prothena Price Performance
NASDAQ:PRTA traded up $0.01 during trading hours on Thursday, reaching $8.36. 296,699 shares of the company were exchanged, compared to its average volume of 506,926. The company has a market capitalization of $429.29 million, a P/E ratio of -17.42, a P/E/G ratio of 4.33 and a beta of -0.20. Prothena Corporation plc has a 1-year low of $7.70 and a 1-year high of $11.80. The business has a 50 day moving average of $8.46 and a 200 day moving average of $9.15.
Prothena (NASDAQ:PRTA – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The biotechnology company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.09). The company had revenue of $0.62 million for the quarter, compared to the consensus estimate of $9.58 million. Prothena had a negative return on equity of 9.98% and a negative net margin of 45.44%. As a group, equities research analysts anticipate that Prothena Corporation plc will post 0.06 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
PRTA has been the topic of several analyst reports. UBS Group reissued a “buy” rating on shares of Prothena in a report on Friday, July 24th. Weiss Ratings downgraded Prothena from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, October 29th. Wall Street Zen cut shares of Prothena from a “buy” rating to a “hold” rating in a research report on Saturday, July 25th. Finally, HC Wainwright initiated coverage on shares of Prothena in a research report on Friday, November 6th. They set a “strong-buy” rating for the company. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Prothena presently has a consensus rating of “Moderate Buy” and an average target price of $20.00.
View Our Latest Analysis on PRTA
Institutional Investors Weigh In On Prothena
A number of large investors have recently modified their holdings of the business. Rubric Capital Management LP lifted its position in shares of Prothena by 36.0% during the 1st quarter. Rubric Capital Management LP now owns 5,000,000 shares of the biotechnology company’s stock worth $48,600,000 after buying an additional 1,322,669 shares during the last quarter. ADAR1 Capital Management LLC grew its position in Prothena by 8.5% in the first quarter. ADAR1 Capital Management LLC now owns 1,581,443 shares of the biotechnology company’s stock valued at $15,372,000 after acquiring an additional 123,679 shares during the last quarter. Renaissance Technologies LLC grew its position in Prothena by 39.5% in the first quarter. Renaissance Technologies LLC now owns 607,515 shares of the biotechnology company’s stock valued at $5,905,000 after acquiring an additional 172,000 shares during the last quarter. Engineers Gate Manager LP acquired a new position in Prothena during the second quarter worth about $404,000. Finally, Headlands Technologies LLC acquired a new position in Prothena during the second quarter worth about $148,000. Institutional investors and hedge funds own 97.08% of the company’s stock.
Prothena Company Profile
Prothena Corporation plc is a clinical-stage biotechnology company developing treatments for diseases associated with protein misfolding and dysfunction. Its research focuses on using antibodies and other biologic approaches to target proteins implicated in neurological and systemic disorders. The company’s pipeline has included programs for Parkinson’s disease, Alzheimer’s disease and AL amyloidosis. Its investigational therapies include prasinezumab, developed in collaboration with Roche, and programs targeting amyloid beta and transthyretin-related disease.
Recommended Stories
- Five stocks we like better than Prothena
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.
